ClinicalTrials.gg
CompletedNCT01985373NanogamUpdated Apr 6, 2015

Pharmacokinetics and Safety of IVIG Nanogam 100 mg/ml

A Phase 3 interventional study of Intravenous immunoglobulin infusion in Primary Immunodeficiency, sponsored by Prothya Biosolutions. Completed at 4 sites in Netherlands. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2015-04-06.

Sponsored by Prothya Biosolutions · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
23
Allocation
Not applicable
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 27 studies testing Immunoglobulins, Intravenous in Primary Immunodeficiency Diseases — 2 open to participants now, 4 under way, 4 of them phase 3. Immunoglobulins, Intravenous · Primary Immunodeficiency Diseases.

Enrollment
20th of 26
23 · median 45
Started
2013
with 1 other
Phase 3
18 of 27
2 open now
Registered
18th of 27
by date
Lead sponsor
1 of 27
Prothya Biosolutions

Among the 27 studies testing Immunoglobulins, Intravenous in Primary Immunodeficiency Diseases, this one is the 20th largest by enrollment of the 26 interventional ones that give a count, is one of 2 that started in 2013, is one of 18 in phase 3, and was the 18th registered.

Primary Immunodeficiency Diseases

211 studies on the registry are indexed under Primary Immunodeficiency Diseases; 51 are open to participants now.

Browse Primary Immunodeficiency Diseases studies →

Open to participants now

2 of the 27 studies testing Immunoglobulins, Intravenous in Primary Immunodeficiency Diseases are open now. Recruiting first, the newest first:

All 2 open studies →

About Immunoglobulins, Intravenous

Immunoglobulins, Intravenous: first FDA approval 1944 (Baygam, Gamastan S/D), first EMA approval 2006. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 35 Primary Immunodeficiency Diseases studies recruiting now, 12 (34%) set no upper age limit and 10 (29%) stop at 75 or younger; 28 take children under 18; 11 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 27 studies testing Immunoglobulins, Intravenous in Primary Immunodeficiency Diseases, or all of them as a file.
02

Study summary

Intravenous immunoglobulin (IVIG) is used for treatment of a heterogeneous group of immune related disorders both as immune-replacement and immune-modulating therapy. Sanquin developed a 100 mg/ml IVIg product (Nanogam 100 mg/ml). Patient will receive one infusion with Nanogam 50 mg/ml as they used to (same dose) and subsequently 4 infusions with Nanogam 100 mg/ml (same dose). Aim is to show bioequivalency between the 50 mg/ml and the 100 mg/ml product of Sanquin.

03

Conditions studied

  • Primary Immunodeficiency

Keywords

  • intravenous immunoglobulin
  • pharmacokinetics
  • 10% IVIG
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Primary a- or hypogammaglobulinemia, particularly patients with XLA or CVID
  • Stabilised on treatment with Nanogam 50 mg/ml with 2-4 weeks intervals in an hospital or at home and willing to be treated with 1 infusion of Nanogam 50 mg/ml and 4 infusions of Nanogam 100 mg/ml at the hospital
  • A stable clinical situation (no activity of any other disease; a stable immunoglobulin dose and frequency)
  • Age >= 18 years
  • The patient has signed the consent form

Exclusion criteria

Exclusion Criteria:

  • Known with allergic reactions against human plasma or plasma products
  • Having an ongoing progressive disease, including infection
  • Pregnancy or lactation
  • Known with insufficiency of coronary or cerebral circulation
  • Having renal insufficiency (plasma creatinin > 115µmol/L)
  • Having IgA deficiency and anti-IgA antibodies have been detected
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
23 participants (actual)

Study arms

  • Experimental
    Intravenous immunoglobulin infusion

    One intravenous infusion with Nanogam 50 mg/ml and 4 with Nanogam 100 mg/ml (0.2-0.8 g/kg)

    Drug: Intravenous immunoglobulin infusion

Interventions

  • Blood samples are drawn before infusion with Nanogam 50 and Nanogam 100 mg/ml and IgG levels are determined to study PK

    Also known as: Nanogam

06

What researchers measure

Primary outcomes

  1. IgG trough levels

    Comparison IVIG 5% and 10%

    Time frame: before infusion

  2. plasma concentration-time curve

    Comparison IVIG 5% and 10%

    Time frame: predose, 1 hour, 2 hours and 1, 2, 3, 7, 14 and 21 days post-dose

  3. half-life

    Comparison IVIG 5% and 10%

    Time frame: predose, 1 hour, 2 hours and 1, 2, 3, 7, 14 and 21 days post-dose

  4. area under the curve

    Comparison IVIG 5% and 10%

    Time frame: predose, 1 hour, 2 hours and 1, 2, 3, 7, 14 and 21 days post-dose

  5. volume of distribution

    Comparison IVIG 5% and 10%

    Time frame: predose, 1 hour, 2 hours and 1, 2, 3, 7, 14 and 21 days post-dose

  6. Cmax

    Comparison IVIG 5% and 10%

    Time frame: predose, 1 hour, 2 hours and 1, 2, 3, 7, 14 and 21 days post-dose

  7. Tmax

    Comparison IVIG 5% and 10%

    Time frame: predose, 1 hour, 2 hours and 1, 2, 3, 7, 14 and 21 days post-dose

  8. elimination rate constant(s)

    Comparison IVIG 5% and 10%

    Time frame: predose, 1 hour, 2 hours and 1, 2, 3, 7, 14 and 21 days post-dose

Secondary outcomes

  1. Adverse Events

    number and type

    Time frame: from first till 3 weeks after last infusion (11-19 weeks dependent on infusion frequency)

07

Study locations

4 sites
  • Jeroen Bosch Ziekenhuis
    Den Bosch, Netherlands
  • UMCG
    Groningen, Netherlands
  • LUMC
    Leiden, Netherlands
  • UMC St. Radboud
    Nijmegen, Netherlands
08

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Dec 2013, a primary completion of Mar 2015 and a completion of Mar 2015. It does not say whether these dates are actual or estimated.

How these figures are worked out, and which studies are left out of them.

Registered
Oct 31, 2013
First posted
Nov 15, 2013
Start
Dec 2013
Primary completionActual
Mar 2015
CompletionActual
Mar 2015
Last update
Apr 6, 2015
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Apr 6, 2015, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT01985373
Lead sponsor
Prothya Biosolutions
Responsible party
Sponsor
First posted
Nov 15, 2013
Start date
Dec 2013
Primary completion
Mar 2015
Completion
Mar 2015
Last update
Apr 6, 2015

Study contacts

F P Kroon, PhD, MD
principal investigator · LUMC

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Apr 2015. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Immunoglobulins, Intravenous

Start the discussion